Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05458128

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

Conditions: Idiopathic Hypersomnia, Excessive Daytime Sleepiness

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 119
Sponsor: Harmony Biosciences Management, Inc.

Location: Cedars-Sinai Medical Towers Los Angeles California

Summary

The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) who completed the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010.

Eligibility Criteria

Inclusion Criteria: 1. Is able to provide voluntary, informed consent. 2. Completed the Double-Blind Randomized Withdrawal Phase (EOT/Visit 5) from the HBS-101-CL-010 study. 3. A patient who is a female of child-bearing potential must have a negative urine pregnancy test at the Screening Visit. A patient who is a female of child-bearing potential must agree to remain abstinent or use an effective method of non-hormonal contraception to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug. 4. Must have a negative result on urine drug screen at the Screening Visit, except for medications that are prescribed by a healthcare provider for medical conditions. 5. In the opinion of the Investigator, the patient is capable of understanding and complying with the protocol and administration of oral study drug. Exclusion Criteria: 1. Does not agree to discontinue any prohibited medication or substances listed in the protocol. 2. Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 21 days after final dose of study drug. 3. Participation in an interventional research study with an investigational medication or device, other than pitolisant, for the duration of the study. 4. Has a diagnosis of end-stage renal disease (ESRD; estimated glomerular filtration rate \[eGFR\] of \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05458128). StuddyBuddy aggregates publicly available trial information.